330 related articles for article (PubMed ID: 31721602)
1. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
2. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
[TBL] [Abstract][Full Text] [Related]
3. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
5. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
6. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
7. Lanadelumab to treat hereditary angioedema.
Wedi B
Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
[TBL] [Abstract][Full Text] [Related]
8. Lanadelumab: First Global Approval.
Syed YY
Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
[TBL] [Abstract][Full Text] [Related]
9. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
10. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
Magerl M; Schiffhorst G; Fanter L; Müller G; Hirche C; Berkemeier F; Aygören E
Allergy; 2024 Jan; 79(1):215-224. PubMed ID: 37641968
[TBL] [Abstract][Full Text] [Related]
11. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
Bova M; Valerieva A; Wu MA; Senter R; Perego F
Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
[TBL] [Abstract][Full Text] [Related]
12. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
Hioki C; Oda Y; Moriwaki S; Fukunaga A
J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
[TBL] [Abstract][Full Text] [Related]
13. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
14. A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema.
Villavicencio MF; Craig T
Expert Rev Clin Immunol; 2020 May; 16(5):451-455. PubMed ID: 32237900
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
Hide M; Ohsawa I; Nurse C; Yu M;
J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
17. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
[TBL] [Abstract][Full Text] [Related]
18. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of hereditary angioedema.
Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
[TBL] [Abstract][Full Text] [Related]
20. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
